Aignostics today announced the general availability of Atlas H&E-TME, following the success of early access pilots with several leading biopharma organizations. This advanced application is designed to analyze the tumor microenvironment (TME) directly from routine H&E images, removing the need for specialized staining or multiplexing. By enabling comprehensive whole-slide image analysis within hours, Atlas H&E-TME allows cancer researchers to gain deep insights into immune cell composition, spatial organization, and overall tissue architecture across multiple tumor types—accelerating discoveries in oncology research.
Developed on Atlas, the foundational model co-created by Aignostics, Mayo Clinic, and Charité Berlin, the new application represents a major leap forward in computational pathology. It provides high-resolution readouts across seven distinct tissue categories and nine cell classes while generating over 5,000 advanced quantitative metrics per image. The platform also incorporates automated quality control and offers a self-service interface that seamlessly integrates with major image management systems, with full integration support set to roll out soon. To ensure reliability in real-world settings, the solution has undergone extensive validation across primary and metastatic tissue samples from different laboratories and imaging scanners. Validation data is available to new research partners upon request.
Dr. Frederick Klauschen, Co-Founder of Aignostics and Director of the Institute of Pathology at Ludwig-Maximilians-Universität München, praised the breakthrough, stating, “This is the first model I’ve seen that maintains consistently high accuracy across diverse cancer types.” Viktor Matyas, Co-Founder and CEO of Aignostics, added, “Decoding the TME is vital for advancing cancer therapies, yet traditional methods are slow, costly, and often limited in scale. Atlas H&E-TME revolutionizes this process—our biopharma partners have already seen exceptional precision, speed, and scalability, maximizing the value of every H&E image.”
Atlas H&E-TME supports a wide range of oncology research applications, from identifying tumors with immune infiltration to combining H&E data with spatial transcriptomics for more detailed cell niche mapping. The platform is now available to biopharma partners focusing on breast, bladder, colorectal, liver, and lung cancers, with academic access and additional cancer models planned for future release.
